Primary Tumor Resection for M1a Stage Lung Cancer

Launched by FUDAN UNIVERSITY · Aug 7, 2024

Keywords

ClinConnect Summary

This clinical trial, called ECTOP-1023, is investigating whether removing the primary tumor in patients with M1a stage lung cancer—where the cancer has spread to the lining of the lungs—can improve survival and quality of life. The researchers want to see if this surgical procedure can help patients live longer and feel better after treatment. The study is currently looking for participants aged 18 to 80 who have not had previous lung cancer surgery and have been diagnosed with this specific stage of lung cancer.

To be eligible, participants should be able to follow the study guidelines and have a good performance status, meaning they can carry out daily activities with little or no difficulty. Patients who join the trial will undergo surgery to remove the tumor and will be monitored to assess the outcomes. It’s important to note that individuals who have received prior treatments like chemotherapy or radiation, or who have other types of lung cancer, will not be eligible for this study. If you or a loved one is considering participating, it could be a valuable opportunity to contribute to research that may help improve treatment options for lung cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Volunteer to participate in clinical research, willing to follow and able to complete all trial procedures;
• • 2. Aged 18-80 years (including critical values) when signing the informed consent form;
• • 3. ECOG score 0 or 1;
• • 4. No previous lung cancer surgery;
• • 5. Intraoperative or postoperative pathological confirmation of M1a stage lung cancer;
• • 6. Occult pleural metastasis found during surgery;
• • 7. Preoperative lymph node staging is cN0;
• • 8. First-time treatment and no radiotherapy or chemotherapy.
• Exclusion Criteria:
• • 1. The lesion cannot be completely removed surgically;
• • 2. Cytological or histological pathology confirms other lung malignancies other than lung cancer;
• • 3. Patients who have undergone lung cancer surgery before;
• • 4. Patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.